Discover this podcast and so much more

Podcasts are free to enjoy without a subscription. We also offer ebooks, audiobooks, and so much more from just $11.99/month.

Nirav Shah, MD, MS / Dr. Toby A. Eyre, MBChB, DipMedEd, MRCP, FRCPath, MD - Reviving the BTK Target in MCL: Recalibrating the Treatment Sequence With Non-Covalent BTK Inhibitors in R/R Disease

UNLIMITED

Nirav Shah, MD, MS / Dr. Toby A. Eyre, MBChB, DipMedEd, MRCP, FRCPath, MD - Reviving the BTK Target in MCL: Recalibrating the Treatment Sequence With…

FromPeerView Internal Medicine CME/CNE/CPE Audio Podcast


UNLIMITED

Nirav Shah, MD, MS / Dr. Toby A. Eyre, MBChB, DipMedEd, MRCP, FRCPath, MD - Reviving the BTK Target in MCL: Recalibrating the Treatment Sequence With…

FromPeerView Internal Medicine CME/CNE/CPE Audio Podcast

ratings:
Length:
64 minutes
Released:
Nov 24, 2023
Format:
Podcast episode

Description

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/CPE/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/GYD865. CME/MOC/NCPD/CPE/AAPA/IPCE credit will be available until November 26, 2024.Reviving the BTK Target in MCL: Recalibrating the Treatment Sequence With Non-Covalent BTK Inhibitors in R/R DiseaseCovalent BTK inhibitors (cBTKi) have transformed the management of mantle cell lymphoma (MCL). However, their efficacy as second-line therapies is often hindered by intolerance and treatment resistance, leading to poor outcomes for many patients with relapsed/refractory (R/R) disease who discontinue cBTKi. Are you prepared to overcome this challenge by developing evidence-based sequential strategies for MCL treatment? Find out how to “revive” the BTK target by joining two MCL experts as they explore the integration of non-covalent BTKi (ncBTKi) in sequential R/R MCL care. Throughout, the experts use robust case discussion and 3D and 2D animations to provide guidance on developing ncBTKi-inclusive treatment plans that deliver safe and highly effective care while extending the clinical benefits of BTKi therapy.Co-Chair and ModeratorNirav Shah, MD, MSFroedtert Hospital and the Medical College of WisconsinMilwaukee, WisconsinCo-Chair and PresenterDr. Toby A. Eyre, MBChB, DipMedEd, MRCP, FRCPath, MDOxford University HospitalsNHS Foundation TrustOxford, United Kingdom In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Lilly.Disclosure PolicyPVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by or used on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresCo-Chair/PlannerNirav Shah, MD, MS, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Bristol Myers Squibb-Juno Therapeutics Inc; Epizyme, Inc.; Incyte Corporation; Janssen Pharmaceuticals, Inc.; Kite, A Gilead Company; Loxo Oncology-Lilly; Miltenyi Biotec; Novartis Pharmaceuticals Corporation; Seattle Genetics, Inc.; TG Therapeutics, Inc.; and Umoja Biopharma.Grant/Research Support from Loxo Oncology-Lilly and Miltenyi Biotec.Co-Chair/PlannerDr. Toby A. Eyre, MBChB, DipMedEd, MRCP, FRCPath, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie; AstraZeneca; BeiGene; F. Hoffmann-La Roche AG; Gilead Sciences, Inc.; Janssen Pharmaceuticals, Inc.; Kite, A Gilead Company; Lilly; Loxo Oncology, Inc.; and Secura Bio, Inc.Grant/Research Support from AstraZeneca and BeiGene.Speaker for AbbVie; AstraZeneca; F. Hoffmann-La Roche AG; Gilead Sciences, Inc.; Janssen Pharmaceuticals, Inc.; Kite, A Gilead Company; Lilly; and Loxo Oncology, Inc.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.
Released:
Nov 24, 2023
Format:
Podcast episode

Titles in the series (100)

PeerView (PVI) is a leading provider of high-quality, innovative continuing education (CME/CE/CPE and MOC) for clinicians and their interprofessional teams. Combining evidence-based medicine and instructional expertise, PeerView activities improve the knowledge, skills, and strategies that support clinical performance and patient outcomes. PeerView makes its educational programming and expert-led presentations and symposia available through its network of popular podcast channels to support specific specialties and conditions. Each episode includes a link to request CME/CE credit for participation. PeerView is solely responsible for the selection of topics, the preparation of editorial content, and the distribution of all materials it publishes.